|
30
|
|
Arginine rewires eIF4F translation initiation to overcome fever-induced CAR T cell dysfunction.
(linkinghub.elsevier.com)
|
Kondo T
…
Taylor N
Cell Metabolism
2026-10-28
|
#immunotherapy
#car-t
#metabolism
#translation
#leukemia
|
|
28
|
|
Milestone cancer vaccine success leaves hard questions unanswered.
(science.org)
|
Kaiser J
Science
2026-10-29
|
#vaccination
#immunotherapy
#melanoma
#rna
|
|
25
|
|
Antibiotics and outcomes of cancer immunotherapy: An updated meta-analysis and clinical applications.
(linkinghub.elsevier.com)
|
Porcari S
…
Zitvogel L
Cancer Cell
2026-10-27
|
#microbiome
#immunotherapy
#antibiotic
#dysbiosis
#cancer
|
|
24
|
|
PD-L1 expression in germinal centers promotes humoral immunity by restricting T follicular regulatory cell differentiation.
(linkinghub.elsevier.com)
|
Akama-Garren EH
…
Carroll MC
Immunity
2026-10-28
|
#immunity
#germinal center
#immunotherapy
#autoimmunity
|
|
24
|
|
T cell cross-priming by PD-L1(+) type 1 conventional dendritic cells mediates the antitumor efficacy of a PD-L1x4-1BB bispecific antibody.
(linkinghub.elsevier.com)
|
Luri-Rey C
…
Melero I
Immunity
2026-10-28
|
#immunotherapy
#dendritic cell
#cancer
#antigen-presentation
#activation
|
|
19
|
|
Tumour assembloids recapitulate tumour-CAF-T cell crosstalk in renal cancer.
(nature.com)
|
Kim E
…
Shin K
Nature
2026-10-28
|
#immunotherapy
#microenvironment
#t cell
#organoid
#renal-cancer
|
|
17
|
|
Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.
(nature.com)
|
Reck M
…
Spicer J
Nature Medicine
2026-10-26
|
#immunotherapy
#lung cancer
#neoadjuvant
#clinical trial
#chemotherapy
|
|
16
|
|
T cell-mediated depletion of intratumoral regulatory T cells using a CCR8xCD3 T cell-engaging bispecific antibody (TCB) promotes antitumor immunity in preclinical mouse models.
(science.org)
|
Wang B
…
Junttila TT
Science Translational Medicine
2026-10-28
|
#cancer
#immunotherapy
#t-cells
#immunity
#antibody
|
|
16
|
|
B cell subsets are associated with durable responses in distinct cancer types after immune checkpoint inhibition.
(science.org)
|
Kim SS
…
Sharabi AB
Science Translational Medicine
2026-10-28
|
#cancer
#immunotherapy
#b cell
#immunity
#transcriptomics
|
|
16
|
|
Brain-sensing synNotch-CAR T cells enable precise targeting and clearance of diffuse midline glioma in multiple preclinical models.
(science.org)
|
Lakshmanachetty S
…
Okada H
Science Translational Medicine
2026-10-28
|
#car-t
#glioma
#immunotherapy
#synthetic biology
#neurotoxicity
|
|
13
|
|
Glucose restriction induced by intermittent fasting promotes alternative metabolic fluxes leading to memory CD8(+) T cell development.
(science.org)
|
Park DJ
…
Yun CH
Science Advances
2026-10-28
|
#metabolism
#immunity
#immunotherapy
#memory
#epigenetics
|
|
13
|
|
A systematic pan-cancer analysis of intratumoral microbiota-derived epitopes to inform cancer immunotherapy and prevention.
(science.org)
|
Li D
…
Xu J
Science Advances
2026-10-28
|
#microbiome
#cancer
#immunotherapy
#epitopes
#vaccination
|
|
13
|
|
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC.
(nejm.org)
|
Zhou F
…
Zhou C
New England Journal of Medicine
2026-10-25
|
#clinical trial
#immunotherapy
#nsclc
#oncology
#checkpoint inhibitor
|
|
13
|
|
Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.
(nejm.org)
|
Skoulidis F
…
Solomon BJ
New England Journal of Medicine
2026-10-25
|
#clinical trial
#nsclc
#oncology
#mutation
#immunotherapy
|
|
11
|
|
Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.
(linkinghub.elsevier.com)
|
Xu CR
…
Wu YL
The Lancet
2026-10-26
|
#clinical trial
#lung cancer
#oncology
#immunotherapy
#targeted therapy
|
|
11
|
|
Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.
(linkinghub.elsevier.com)
|
Lorusso D
…
Pothuri B
The Lancet
2026-10-26
|
#clinical trial
#endometrial-cancer
#immunotherapy
#antibody-drug conjugates
#chemotherapy
|
|
11
|
|
First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.
(linkinghub.elsevier.com)
|
Slomovitz BM
…
Pignata S
The Lancet
2026-10-26
|
#clinical trial
#immunotherapy
#endometrial-cancer
#chemotherapy
#mismatch-repair
|
|
11
|
|
Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.
(linkinghub.elsevier.com)
|
Hong S
…
Yang Y
The Lancet
2026-10-26
|
#cancer
#clinical trial
#immunotherapy
#lung
#chemotherapy
|
|
11
|
|
Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.
(linkinghub.elsevier.com)
|
Lan B
…
Xu B
The Lancet
2026-10-26
|
#breast cancer
#clinical trial
#immunotherapy
#chemotherapy
#targeted therapy
|
|
9
|
|
Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.
(nature.com)
|
Necchi A
…
Lichtenegger FS
Nature Medicine
2026-10-24
|
#immunotherapy
#bladder cancer
#neoadjuvant
#clinical trial
#checkpoint inhibitor
|